Sign up for your free ClinicalKey trial today! Your first step in getting the right answers
when you need them.
Complications and Prognosis
Screening and Prevention
Severe bleeding or bleeding refractory to standard outpatient care
Patients with hemophilia B who are being newly treated or who have developed inhibitors to factor IX are at risk for anaphylaxis or other severe allergic manifestations; therefore, it is recommended that blood or factor IX products to which the patient has not been exposed be administered for the first 10 to 20 times in a hospital or other supervised medical setting in which severe allergic reactions can be adequately managed r5
Mainstay of treatment consists of replacing factor IX, though the approval of gene therapy may alter the landscape of treatment in upcoming years
Factor IX replacement
Management of factor IX inhibitors r5
Additional considerations for bleeding episodes
All patients with hemophilia B should be immunized against hepatitis A and B r5
Avoid drug products containing aspirin or NSAIDs c86c87
Avoid long-term opioid use r5
Administer hepatitis A and B vaccines to all nonimmune patients with hemophilia r5
Cookies are used by this site. To decline or learn more, visit our cookie notice.